Mikhail Eydelman - 07 Nov 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: SVP, GEN COUNSEL & CORP SEC
Issuer ticker: PCVX
Reported as of: 07 Nov 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Nov 2024, 20:50:17 UTC
Prior SEC filing: 06 Nov 2024
Next SEC filing: 09 Dec 2024
Source filing: View source filing
Reporting owner signature: Mikhail Eydelman, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

Mikhail Eydelman filed Form 4 for Vaxcyte, Inc. (PCVX) on 08 Nov 2024.

Key facts

This page summarizes Mikhail Eydelman's Form 4 filing for Vaxcyte, Inc. (PCVX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Nov 2024, 20:50.

Change

Previous filing in this sequence was filed on 06 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Performance Stock Option (right to buy)

Award

Transaction value: $0
Shares: +26,125
Change %
Price: $0.000000
Shares after: 26,125
Date: 07 Nov 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,125
Exercise price: $102.70
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 26,125 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)).